Merck To Distribute CSL Flu Vaccine

Australia-based CSL, maker of seasonal flu vaccine Afluria, reached a deal with Merck & Co., to exclusively market and distribute the vaccine in the U.S. for 6 years.

NEW YORK (AP) -- CSL Ltd. and its unit CSL Biotherapies on Monday said it reached a marketing and distribution deal with drug developer Merck & Co. for the seasonal flu vaccine Afluria.

Financial details of the deal were not disclosed.

Australia-based CSL makes Afluria, which is sold in both pre-filled syringes and multi-dose vials. Under the deal, CSL has a six-year, exclusive marketing and distribution deal in the U.S.

Whitehouse Station, N.J.-based Merck will have exclusive sales and distribution rights in the U.S. beginning with the 2010-2011 flu season. CSL will retain the license.

Shares of Merck rose 30 cents to $31.55 in premarket trading.

More in Global